Wedbush Downgrades Sangamo BioSciences (SGMO) to Neutral

Wedbush downgraded Sangamo BioSciences (NASDAQ: SGMO) from Outperform to Neutral with a price target of $4.00.

Analyst Liana Moussatos commented, "While we believe Sangamo's new management has positively reorganized the company for the longer term with clear goals and reliable success, the pipeline overhaul has created a gap and lack of material clinical catalysts for the Street until 2018. Consequently, we are downgrading to Neutral and view SGMO as appropriate for investors with a longer-term horizon."

For an analyst ratings summary and ratings history on Sangamo BioSciences click here. For more ratings news on Sangamo BioSciences click here.

Shares of Sangamo BioSciences closed at $3.55 yesterday.

You May Also Be Interested In

• Increasing unusual option volume: SGMO MGA MTTR IPG HUYA WSC
• Northland Downgrades Matterport, Inc (MTTR) to Market Perform
• Evercore ISI Downgrades SunPower (SPWR) to In Line